The Cancer Biology (CBIO) program promotes intra- and inter-programmatic collaborative research for discovery of the molecular and cellular basis of cancer.
The future of cancer therapy centers on the identification of drivers of disease, both as individual targets as well as signaling networks unique to, or highjacked by, cancer cells. These target identification and validation efforts are followed by the development of new agents or repurposing of existing agents to target the drivers.
The CBIO program has an outstanding cadre of investigators with expertise that spans all of these efforts. This includes well-demonstrated expertise in target identification and validation, analysis of signaling pathways, and the development of small molecule inhibitors for drivers of many different forms of cancer.
The program is organized around two main themes:
- Define targets that support cancer cell survival and proliferation: This includes efforts to identify and validate targets for small molecule modulators as well as the development of small molecule modulators of function.
- Elucidate mechanisms driving cancer: Elucidate properties of cancer cell signaling networks and how they support tumor initiation and metastasis.
The program is led by John Bushweller, PhD, a leader in structure/function and inhibitor development focused on transcription factors, Dan Gioeli, PhD, a leader in signaling and 3D tumor models, and David Brautigan, PhD, a world leader in phosphatase function and signaling.
The CBIO program aims to facilitate interaction among members to enhance the likelihood of collaborative efforts, assist in efforts to develop multiple investigator projects both within CBIO and with other programs, and aid in efforts to move discoveries forward along the translational pipeline.
Learn more about program members and their research interests.